Mutual of America Capital Management LLC Cuts Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Mutual of America Capital Management LLC cut its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 4.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 93,729 shares of the company’s stock after selling 3,954 shares during the period. Mutual of America Capital Management LLC owned about 0.19% of Amphastar Pharmaceuticals worth $3,749,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. YHB Investment Advisors Inc. acquired a new stake in Amphastar Pharmaceuticals in the 1st quarter valued at about $27,000. Principal Securities Inc. acquired a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $34,000. Innealta Capital LLC acquired a new stake in Amphastar Pharmaceuticals in the second quarter valued at approximately $55,000. Quadrant Capital Group LLC lifted its stake in Amphastar Pharmaceuticals by 27.8% in the fourth quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after acquiring an additional 223 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after acquiring an additional 309 shares in the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the completion of the sale, the director now owns 75,409 shares in the company, valued at approximately $3,504,256.23. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, Director Floyd F. Petersen sold 3,000 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the transaction, the director now owns 75,409 shares of the company’s stock, valued at $3,504,256.23. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Rong Zhou sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the sale, the executive vice president now directly owns 118,388 shares of the company’s stock, valued at $5,724,059.80. The disclosure for this sale can be found here. Insiders have sold 37,979 shares of company stock worth $1,671,307 in the last quarter. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Trading Down 1.8 %

Shares of Amphastar Pharmaceuticals stock opened at $49.18 on Monday. The company has a current ratio of 3.52, a quick ratio of 2.63 and a debt-to-equity ratio of 0.82. The company has a fifty day simple moving average of $44.56 and a 200-day simple moving average of $42.61. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of 17.02, a PEG ratio of 0.85 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The company had revenue of $182.39 million for the quarter, compared to analyst estimates of $171.29 million. On average, equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.71 EPS for the current fiscal year.

Analysts Set New Price Targets

AMPH has been the topic of a number of analyst reports. Piper Sandler reduced their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Finally, StockNews.com raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $63.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.